AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders
Journal of Child and Adolescent Psychopharmacology2006Vol. 16(5), pp. 589–598
Citations Over TimeTop 10% of 2006 papers
Lawrence David Scahill, Michael G. Aman, Christopher J. McDougle, James T. McCracken, Elaine Tierney, James Dziura, L. Eugene Arnold, David J. Posey, Christopher Young, Bhavik Shah, Jaswinder K. Ghuman, Louise Ritz, Benedetto Vitiello
Abstract
Guanfacine may be useful for the treatment of hyperactivity in children with PDD. Placebo-controlled studies are needed to guide clinical practice.
Related Papers
- → A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder(2008)187 cited
- → Levels of Proneness to Boredom in Children with Attention-Deficit/Hyperactivity Disorder On and Off Methylphenidate Treatment(2020)25 cited
- → Polypharmacy in Attention-Deficit/Hyperactivity Disorder: More Than the Sum of Its Parts?(2016)2 cited
- Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment(2016)
- → Results of N=1 randomized, double-blind, placebo-controlled, cross-over discontinuation trials embedded in clinical practice after longer term methylphenidate use: A pilot study(2023)